These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19343970)

  • 21. Levodopa and childhood amblyopia.
    Leguire LE; Rogers GL; Bremer DL; Walson P; Hadjiconstantinou-Neff M
    J Pediatr Ophthalmol Strabismus; 1992; 29(5):290-8; discussion 299. PubMed ID: 1432516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does levodopa improve vision in albinism? Results of a randomized, controlled clinical trial.
    Summers CG; Connett JE; Holleschau AM; Anderson JL; De Becker I; McKay BS; Brilliant MH
    Clin Exp Ophthalmol; 2014 Nov; 42(8):713-21. PubMed ID: 24641678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy.
    Perry D; Birthi P; Salles S; McDowell S
    PM R; 2012 May; 4(5):383-4. PubMed ID: 22613365
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficiency of the occlusion therapy with and without levodopa-carbidopa in amblyopic children-A tertiary care centre experience.
    Sofi IA; Gupta SK; Bharti A; Tantry TG
    Int J Health Sci (Qassim); 2016 Apr; 10(2):249-57. PubMed ID: 27103907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of levodopa as treatment for residual amblyopia in older children.
    ; Repka MX; Kraker RT; Dean TW; Beck RW; Siatkowski RM; Holmes JM; Beauchamp CL; Golden RP; Miller AM; Verderber LC; Wallace DK
    Ophthalmology; 2015 May; 122(5):874-81. PubMed ID: 25676904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial.
    Ford GA; Bhakta BB; Cozens A; Hartley S; Holloway I; Meads D; Pearn J; Ruddock S; Sackley CM; Saloniki EC; Santorelli G; Walker MF; Farrin AJ
    Lancet Neurol; 2019 Jun; 18(6):530-538. PubMed ID: 31122493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy.
    Johnson LN; Guy ME; Krohel GB; Madsen RW
    Ophthalmology; 2000 Mar; 107(3):521-6. PubMed ID: 10711891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occlusion-amblyopia following high dose oral levodopa combined with part time patching.
    Kothari M
    Indian J Ophthalmol; 2014 Dec; 62(12):1163-5. PubMed ID: 23571255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic Evaluation of Levodopa Effect on Visual Improvement in Amblyopia: A Meta-analysis.
    Wang SP; Li QX; Li S
    Clin Neuropharmacol; 2020; 43(1):20-25. PubMed ID: 31738189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
    Ahlskog JE; Muenter MD; Bailey PA; Miller PM
    Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy.
    Lyttle DP; Johnson LN; Margolin EA; Madsen RW
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):757-64. PubMed ID: 26483145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbidopa/levodopa for smoking cessation: a pilot study with negative results.
    Hurt RD; Ahlskog JE; Croghan GA; Offord KP; Wolter TD; Croghan IT; Moyer TP
    Nicotine Tob Res; 2000 Feb; 2(1):71-8. PubMed ID: 11072443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New advances in amblyopia therapy I: binocular therapies and pharmacologic augmentation.
    Kraus CL; Culican SM
    Br J Ophthalmol; 2018 Nov; 102(11):1492-1496. PubMed ID: 29777043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visual acuities and scotomas after one week levodopa administration in human amblyopia.
    Gottlob I; Charlier J; Reinecke RD
    Invest Ophthalmol Vis Sci; 1992 Aug; 33(9):2722-8. PubMed ID: 1639618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The course of moderate amblyopia treated with atropine in children: experience of the amblyopia treatment study.
    Pediatric Eye Disease Investigator Group
    Am J Ophthalmol; 2003 Oct; 136(4):630-9. PubMed ID: 14516802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amblyopia treatment strategies and new drug therapies.
    Pescosolido N; Stefanucci A; Buomprisco G; Fazio S
    J Pediatr Ophthalmol Strabismus; 2014; 51(2):78-86. PubMed ID: 24410693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and tolerability of levodopa eye drops for the treatment of ocular disorders: A randomized first-in-human study.
    Thomson K; Karouta C; Sabeti F; Anstice N; Leung M; Jong T; Maddess T; Morgan IG; Game J; Ashby R
    Clin Transl Sci; 2022 Nov; 15(11):2673-2684. PubMed ID: 36221799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.